Antiviral Drug Resistance Market Scope And Analysis

Report Code : TIPRE00006395
Category : Life Sciences

No. of Pages : 150

Buy Now

Antiviral Drug Resistance Market Analysis, Scope, and Growth by 2031

Buy Now

Antiviral Drug Resistance Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 3.44 Billion
Market Size by 2031	US$ 6.35 Billion
Global CAGR (2023 - 2031)	7.9%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Kits & Reagents Instruments By Disease Indication Human Immunodeficiency Virus Hepatitis Cytomegalovirus By Technology Immunodiagnostics Polymerase Chain Reaction Next Generation Sequencing Other Technologies By End User Hospitals & Clinics Pathology or Diagnostic Laboratories Research Institutes
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	AccuBioTech Co Ltd ACON Laboratories Inc Siemens AG BioM rieux SA Bio Rad Laboratories Inc Danaher Abbott BD F Hoffmann La Roche Ltd Trinity Biotech

Antiviral Drug Resistance Market News and Recent Developments

The antiviral drug resistance market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the antiviral drug resistance market are listed below:

– The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today the publication of new data in the journal Nature showing that an early-stage clinical candidate (JNJ-1802) provides strong protection against dengue in non-human primates and mice. The first-in-class antiviral, which was shown to be safe and well tolerated in a Phase 1 first-in-human clinical study, is now progressing into Phase 2 clinical studies for the prevention and treatment of dengue. (Source: Johnson & Johnson, Press Release, March 2023)
Cipla Limited announced that it has been granted Emergency Use Authorisation(EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. Cipla plans to launch Molnupiravir under the brand name Cipmolnu®. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease. (Source: Cipla, Press Release, May 2021)

Antiviral Drug Resistance Market Report Coverage and Deliverables

The “Antiviral Drug Resistance Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Antiviral Drug Resistance market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Antiviral Drug Resistance market trends, as well as market dynamics such as drivers, restraints, and key opportunities
Detailed PEST/Porter’s Five Forces and SWOT analysis
Antiviral Drug Resistance market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the Antiviral Drug Resistance market
Detailed company profiles